шапка рус.jpg
ISSN 2070-1004 (print)
ISSN 2686-7966 (online)


Адрес: 123182, Москва, ул. Щукинская, д.5 
Полная информация и схема проезда 

    

МЕДИЦИНА КАТАСТРОФ №1•2021

https://doi.org/10.33266/2070-1004-2021-1

Оригинальная статья

Перспективы применения цефтолозана-тазобактама при оказании медицинской помощи пациентам в лечебной медицинской организации третьего уровня и во время проведения межбольничной медицинской эвакуации

Скачать статью в формате pdf

Парванян С.Г., Шелухин Д.А., Ворошилова Т.М.

ФГБУ «Всероссийский центр экстренной и радиационной медицины им. А.М.Никифорова» МЧС России, Санкт-Петербург, Россия

УДК 614.2

С. 35–40

Резюме. Отмечено, что нозокомиальные инфекции являются серьезной угрозой безопасности пациентов стационаров в силу своей высокой распространенности и высокого уровня летальности. Рассмотрены перспективы применения нового антибактериального препарата цефтолозан-тазобактам в качестве стартовой эмпирической терапии у пациентов с высоким риском развития нозокомиальной инфекции, вызванной микроорганизмами с множественной лекарственной устойчивостью, в лечебной медицинской организации (ЛМО) 3-го уровня и во время проведения межбольничной медицинской эвакуации.

Ключевые слова: антибиотикорезистентность, зербакса, межбольничная медицинская эвакуация, нозокомиальная инфекция, лечебная медицинская организация 3-го уровня, тазобактам, цефтолозан, эмпирическая антибактериальная терапия

Для цитирования: Парванян С.Г., Шелухин Д.А., Ворошилова Т.М. Перспективы применения цефтолозана-тазобактама при оказании медицинской помощи пациентам в лечебной медицинской организации третьего уровня и во время проведения межбольничной медицинской эвакуации // Медицина катастроф. 2021. №1. С. 35-40. https://doi.org/10.33266/2070-1004-2021-1-35-40

СПИСОК ИСТОЧНИКОВ

1. Гуманенко Е.К., Огарков П.И., Лебедев В.Ф., Бояринцев В.В., Кузин А.А. Инфекционные осложнения политравм: микробиологические и эпидемиологические аспекты // Вестник хирургии. 2006. Т.165, №5. С. 56-62.

2. Рудь А.А. Прогнозирование, диагностика и профилактика инфекционных осложнений при политравмах: Дис. … к.м.н. СПб., 2008.

3. Lachiewicz A.M., Hauck C.G., Weber D.J., Cairns B.A., van Duin D. Bacterial infec-tions after burn injuries: impact of multidrug resistance // Clinical Infectious Diseases. 2017; 65(12): 2130–6.

4. Лебедев В.Ф. Клинические, эпидемиологические и микробиологические аспекты посттравматического сепсиса // Материалы II съезда анестезиологов-реаниматологов Северо-Запада РФ. Архангельск, 2003. С. 247-248.

5. Селезнев А.Н., Багненко С.Ф., Шапот Ю.Б., Курыгин А.А. Травматическая болезнь и ее осложнения: Руководство для врачей. СПб., 2004.

6. Черненькая Т.В., Годков М.А. «Проблемные» полирезистентные бактерии — возбудители внутрибольничных инфекций у пациентов в критических состояниях (обзор литературы) // Журнал им. Н.В.Склифосовского. Неотложная медицинская помощь. 2015. №3. С. 30–35.

7. Яковлев С.В., Брико Н.И. Сидоренко С.В. Проценко Д.Н. Программа СКАТ (стратегия контроля антимикробной терапии) при оказании стационарной медицинской помощи: Методические рекомендации. М., 2018.

8. Strich J.R., Palmore T.N. Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit // Infect Dis Clin North Am. 2017; 31(3): 535–550.

9. Emine A. Nizam D. Healthcare-associated infections in Intensive Care Units: epidemi-ology and infection control in low-to-middle income countries // The journal of infection in de-veloping countries. 2015; 9(10): 1040-1045.

10. Kalanuria A.A., Zai W., Mirski M. Ventilator-associated pneumonia in the ICU. Criti-cal Care 2014, 18:208.

11. Яковлев С.В., Суворова М.П. Нозокомиальные инфекции мочевыводящих путей // Урология. 2016. № 3, прил. 3. С. 43-62.

12. Van Nieuwkoop C., Bonten T.N., Van’t Wout J.W. Risk factors for bacteremia with uropathogen not cultured from urine in adults with febrile urinary tract infection // Clin. Infect. Dis. 2010; 50: 69–72.

13. Horcajada J.P., Shaw E., Padilla B. Healthcare–associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective mul-ticenter cohort study in the era of antimicrobial resisatnce // Clin. Microbiol. Infect. 2013; 19: 962–968.

14. Goodlet K.J., Nicolau D.P., Nailor M.D. Ceftolozane/tazobactam and ceftaz-idime/avibactam for the treatment of complicated intra-abdominal infections // Therapeutics and Clinical Risk Management 2016:12: 1811–1826.

15. Sartelli M., Chichom-Mefire A., Labricciosa F.M. et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of in-traabdominal infections // World Journal of Emergency Surgery. 2017; 12: 29.

16. Mulani M.S., Kamble E.E., Kumkaret S.N. et al. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance // Frontiers in Microbiology. April 2019. Vol. 10. Art. 539.

17. Founou R.C., Founou L.L., Essack S.Y. Clinical and economic impact of antibiotic re-sistance in developing countries: a systematic review and meta-analysis // PLoS One. 2017, Dec.21; 12(12): e0189621. https://doi.org/10.1371/journal.pone.0189621

18. Tacconelli E., Carrara E., Savoldi A. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis // Lancet Infect. Dis. 18; 318–327.

19. Vincent J.L., Rello J., Marshall J. et al. International study of the prevalence and out-comes of infection in intensive care units // JAMA. 2009; 302(21): 2323–2329.

20. Santajit S., Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE patho-gens // Biomed. Res. Int. 2016; 2016:2475067.

21. Jacoby G.A., Munoz-Price L.S. The new beta-lactamases // NEJM. 2005. Vol.352. № 4. P. 380-391.

22. Giedraitiene A., Vitkauskiene A., Nagniene R., Pavilonis A. Antibiotic resistance mechanisms of clinical important bacteria // Medicina (Kaunas). 2011; 47(3): 137-46.

23. Wright G.D. Bacterial resistance to antibiotics: enzymatic degradation and modifica-tion // Advanced drug delivery reviews. 2005. Vol.57. №10. P. 1451-1470.

24. Scweizer H.P. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered questions // Genetics and molecular research. 2003. Vol. 2. №. 1. P. 48-62.

25. Laverty. G., Gorman S.P., Gilmore B.F. Biomolecular mechanisms of Pseudomonas aeruginosa and Escherichia Coli biofilm formation // Pathogens. 2014. Vol. 3. № 3. P. 596-623.

26. Шайдуллина Э.Р., Эйдельштейн М.В., Склеенова Е.Ю., Сухорукова М.В., Козлов Р.С. Антибиотикорезистентность нозокомиальных карбапенемазопродуцирующих штаммов Enterobacterales в России: результаты эпидемиологического исследования 2014-2016 // Клиническая микробиология и антимикробная химиотерапия. 2018. Т.20. №4. С. 362-369.

27. Karaiskos I., Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how // Antibiotics. 2020; 9: 61.

28. Sebaaly J., Woods J.A., Wargo K.A. A Review of Ceftolozane /Tazobactam for the Treatment of Infections Caused by Multidrug-Resistant Pathogens // Infectious Diseases in Clini-cal Practice. 2018. Vol. 26. № 4.

29. Giacobbe D.R. Bassetti M., De Rosa F.G. et al. Ceftolozane/tazobactam: place in ther-apy // Expert Review of Anti-infective Therapy. ISSN: 1478-7210.

30. Zhanel G.G., Chang. P., Adam H. et al. Ceftolozane/Tazobactam: A Novel Cepha-losporin/b-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli // Drugs. 2014; 74: 31–51.

31. Chandorkar G., Huntington J.A., Gotfried M.H. et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects // J. Antimicrob. Chemother. 2012. Oct; 67(10): 2463-9.

32. Caro L., Larson K., Nicolau D. Lung penetration and PK/PD attainment in pulmonary epithelial lining fluid (ELF) following 3 g administration of Ceftolozane/Tazobactam (TOL/TAZ) to ventilated, critically-ill patients // 28th Annual European Congress of Clinical Microbiology and Infectious Diseases; Madrid, Spain; April 21–24, 2018. abstr P2225.

33. Xiao A.J., Miller B.W., Huntington J.A., Nicolau D.P. Ceftolozane/tazobactam phar-macokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia // J Clin Pharmacol. 2016; Jan; 56(1): 56-66.

34. Инструкция по медицинскому применению препарата Зербакса® ЛП МЗ России 005085. 31.10.2019.

35. Lindberg O., De Geer L., Chew M.S. Nonadherence to antibiotic guidelines in patients admitted to ICU with sepsis is associated with increased mortality: A registry-based, retrospec-tive cohort study // Eur J Anaesthesiol. 2020; Feb; 37(2): 113-120.

36. Дьяков И.Н., Зырянов С.К., Хачатрян Н.Н. Фармакоэкономическая оценка применения препарата цефтолозан + тазобактам при лечении осложнённых нозокомиальных интраабдоминальных инфекций // Качественная клиническая практика. 2019. №2. С. 55-68.

Материал поступил в редакцию 09.07.20; статья принята после рецензирования 09.09.20; статья принята к публикации 30.11.20



DISASTER MEDICINE No. 1•2021

https://doi.org/10.33266/2070-1004-2021-1

Original article

Prospects for Use of Ceftolosan-Tazobactam in Providing Medical Care to Victims in a Third-Level Hospital and during Inter-Hospital Medical Evacuation

Download the article in pdf format

Parvanyan S.G., Shelukhin D.A., Voroshilova T.M.

Nikiforov Russian Centre of Emergency and Radiation Medicine, EMERCOM of Russia, St. Petersburg, Russian Federation

UDC 614.2

Pp. 35–40

Abstract. It is noted that nosocomial infections are a serious threat to the safety of hospital patients due to their high prevalence and high mortality rate. The prospects of using a new antibacterial drug ceftolosan-tazobactam as a starting empirical therapy in patients with a high risk of nosocomial infection caused by multidrug-resistant microorganisms in a level III hospital and during inter-hospital medical evacuation are considered.

Key words: antibiotic resistance, ceftolosan, empirical antibacterial therapy, inter-hospital medical evacuation, level III hospital, nosocomial infection, tazobactam, zerbaxa

For citation: Parvanyan S.G., Shelukhin D.A., Voroshilova T.M. Prospects for Use of Ceftolosan-Tazobactam in Providing Medical Care to Victims in a Third-Level Hospital and during Inter-Hospital Medical Evacuation. Meditsina Katastrof = Disaster Medicine. 2021; 1: 35-40 (In Russ.). https://doi.org/10.33266/2070-1004-2021-1-35-40

REFERENCES

1. Gumanenko E.K., Ogarkov P.I., Lebedev V.F., Boyarintsev V.V., Kuzin A.A. Infectious Complications of Polytram. Microbiological and Epidemiological Aspects. Vestnik Khirurgii = Annals of Surgery. 2006; 165; 5: 56-62 (In Russ.).

2. Rud' A.A. Prognozirovanie, diagnostika i profilaktika infektsionnykh oslozhneniy pri politravmakh = Forecasting, Diagnosing and Preventing Infectious Complications in Polytrams. Candidate’s thesis in Medicine. St. Petersburg Publ., 2008 (In Russ.).

3. Lachiewicz A.M., Hauck C.G., Weber D.J., Cairns B.A., van Duin D. Bacterial Infec-tions after Burn Injuries: Impact of Multidrug Resistance. Clinical Infectious Diseases. 2017; 65; 12: 2130-6.

4. Lebedev V.F. Klinicheskie, epidemiologicheskie i mikrobiologicheskie aspekty posttravmaticheskogo sepsisa = Clinical, Epidemiological and Microbiological Aspects of Post-Traumatic Sepsis. Materialy II s'ezda anesteziologov-reanimatologov Severo-Zapada RF. Arkhangelsk Publ., 2003; 247-248 (In Russ.).

5. Seleznev A.N., Bagnenko S.F., Shapot Yu.B., Kurygin A.A. Travmaticheskaya bolezn i ee oslozhneniya. Rukovodstvo dlya vrachey = Traumatic Disease and its Complications. St. Petersburg Publ., 2004 (In Russ.).

6. Chernen'kaya T.V., Godkov M.A. "Problematic" Polyressive Bacteria are the Pathogens of Hospital-Acquired Infections in Patients in Critical Conditions. Literature review. Zhurnal im. N.V.Sklifosovskogo. Neotlozhnaya meditsinskaya pomoshch. 2015; 3: 30–35 (In Russ.).

7. Yakovlev S.V., Briko N.I. Sidorenko S.V. Protsenko D.N. Programma SKAT strategiya kontrolya antimikrobnoy terapii pri okazanii statsionarnoy meditsinskoy pomoshchi. Metodicheskie rekomendatsii = The SCAT Program Antimicrobial Therapy Control Strategy in the Provision of Inpatient Care. Moscow Publ., 2018 (In Russ.).

8. Strich J.R., Palmore T.N. Preventing Transmission of Multidrug-Resistant Pathogens in the Intensive Care Unit. Infect Dis Clin North Am. 2017; 31; 3: 535-550.

9. Emine A., Nizam D. Healthcare-Associated Infections in Intensive Care Units: Epide-miology and Infection Control in Low-To-Middle Income Countries. The journal of infection in developing countries. 2015; 9; 10: 1040-1045.

10. Kalanuria A.A., Zai W., Mirski M. Ventilator-Associated Pneumonia in the ICU. Criti-cal Care. 2014; 18: 208.

11. Yakovlev S.V., Suvorova M.P. Nosocomial urinary tract infections. Urologiya. 2016; 3; 3: 43-62 (In Russ.).

12. Van Nieuwkoop C., Bonten T.N., Van’t Wout J.W. Risk Factors for Bacteremia with Uropathogen not Cultured from Urine in Adults with Febrile Urinary Tract Infection. Clin. In-fect. Dis. 2010; 50: 69-72.

13. Horcajada J.P., Shaw E., Padilla B. Healthcare-Associated, Community-Acquired and Hospital-Acquired Bacteraemic Urinary Tract Infections in Hospitalized Patients: a Prospective Multicenter Cohort Study in the Era of Antimicrobial Resisatnce. Clin. Microbiol. Infect. 2013; 19: 962-968.

14. Goodlet K.J., Nicolau D.P., Nailor M.D. Ceftolozane/tazobactam and Ceftaz-idime/Avibactam for the Treatment of Complicated Intra-Abdominal Infections. Therapeutics and Clinical Risk Management. 2016; 12: 1811-1826.

15. Sartelli M., Chichom-Mefire A., Labricciosa F.M. et al. The Management of Intra-Abdominal Infections from a Global Perspective: 2017 WSES guidelines for management of in-traabdominal infections. World Journal of Emergency Surgery. 2017; 12:29.

16. Mulani M.S., Kamble E.E., Kumkaret S.N. et al. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance. Frontiers in Microbiology. April 2019; 10: 539.

17. Founou R.C., Founou L.L., Essack S.Y. Clinical and Economic Impact of Antibiotic Resistance in Developing Countries: a Systematic Review and Meta-Analysis. PLoS One. 2017, Dec. 21; 12; 12: e0189621. https://doi.org/10.1371/journal.pone.0189621

18. Tacconelli E., Carrara E., Savoldi A. et al. Discovery, Research, and Development of New Antibiotics: the Who Priority List of Antibiotic-Resistant Bacteria and Tuberculosis. Lancet Infect. Dis. 18: 318–327.

19. Vincent J.L., Rello J., Marshall J. et al. International Study of the Prevalence and Out-comes of Infection in Intensive Care Units. JAMA. 2009; 302; 21: 2323-2329.

20. Santayit S., Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. Biomed. Res. Int. 2016; 2016; 2475067.

21. Jacoby G.A., Munoz-Price L.S. The New Beta-Lactamases. NEJM. 2005; 352; 4: 380-391.

22. Giedraitiene A., Vitkauskiene A., Nagniene R., Pavilonis A. Antibiotic Resistance Mechanisms of Clinical Important Bacteria. Medicina (Kaunas). 2011; 47; 3: 137-46.

23. Wright G.D. Bacterial Resistance to Antibiotics: Enzymatic Degradation and Modifica-tion. Advanced drug delivery reviews. 2005; 57; 10: 1451-1470.

24. Scweizer H.P. Efflux as a Mechanism of Resistance to Antimicrobials in Pseudomonas Aeruginosa and Related Bacteria: unanswered questions. Genetics and molecular research. 2003; 2; 1: 48-62.

25. Laverty. G., Gorman S.P., Gilmore B.F. Biomolecular Mechanisms of Pseudomonas Aeruginosa and Escherichia Coli Biofilm Formation. Pathogens. 2014; 3; 3: 596-623.

26. Shaydullina E.R., Eydelshteyn M.V., Skleenova E.Yu., Sukhorukova M.V., Kozlov R.S. Antibiotic resistance of nosocomial carbapenemazoduducing strains Enterobacterales in Russia: results of epidemiological study 2014-2016. Klinicheskaya Mikrobiologiya i Antimikrobnaya Khimioterapiya. 2018; 20; 4: 362-369 (In Russ.).

27. Karaiskos I., Giamarellou H. Carbapenem-Sparing Strategies for ESBL Producers: when and how. Antibiotics. 2020; 9: 61.

28. Sebaaly J., Woods J.A., Wargo K.A. A Review of Ceftolozane/Tazobactam for the Treatment of Infections Caused by Multidrug-Resistant Pathogens. Infectious Diseases in Clini-cal Practice. 2018; 26; 4.

29. Giacobbe D.R. Bassetti M., De Rosa F.G. et al. Ceftolozane/Tazobactam: Place in Therapy. Expert Review of Anti-infective Therapy. ISSN: 1478-7210.

30. Zhanel G.G., Chang. P., Adam H. et al. Ceftolozane/Tazobactam: A Novel Cepha-losporin/b-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli Drugs. 2014; 74: 31-51.

31. Chandorkar G., Huntington J.A., Gotfried M.H. et al. Intrapulmonary Penetration of Ceftolozane/Tazobactam and Piperacillin/Tazobactam in Healthy Adult Subjects. J. Antimicrob. Chemother. 2012; Oct; 67; 10: 2463-9.

32. Caro L., Larson K., Nicolau D. Lung Penetration and PK/PD Attainment in Pulmonary Epithelial Lining Fluid (ELF) Following 3 g Administration of Ceftolozane/Tazobactam (TOL/TAZ) to Ventilated, Critically-Ill Patients. 28th Annual European Congress of Clinical Microbiology and Infectious Diseases; Madrid, Spain; April 21–24, 2018. abstr P2225.

33. Xiao A.J., Miller B.W., Huntington J.A., Nicolau D.P. Ceftolozane/Tazobactam Phar-macokinetic/Pharmacodynamic-Derived Dose Justification for Phase 3 Studies in Patients with Nosocomial Pneumonia. J Clin Pharmacol. 2016; Jan; 56; 1: 56-66.

34. Instructions on the medical use of the drug Zerbax. Ministry of Health of the Rissian Federation dated October 31, 2019. No. 005085 (In Russ.).

35. Lindberg O., De Geer L., Chew M.S. Nonadherence to Antibiotic Guidelines in Pa-tients Admitted to ICU with Sepsis is Associated with Increased Mortality: A registry-based, ret-rospective cohort study. Eur J Anaesthesiol. 2020; Feb; 37; 2: 113-120.

36. Dyakov I.N., Zyryanov S.K., Khachatryan N.N. Pharmacoeconomic evaluation of the use of the drug cephtolazane + tazobactam in the treatment of complicated nosocomial intraabdominal infections. Kachestvennaya Klinicheskaya Praktika. 2019; 2: 55-68 (In Russ.).

The material was received 09.07.20; the article after peer review procedure 09.09.20; the Editorial Board accepted the article for publication 30.11.20

© 2009–2020  ФГБУ "Всероссийский центр медицины катастроф ”Защита” ФМБА России


Яндекс.Метрика